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AbstrACt
Objective To establish the level of opioid prescribing for 
patients with chronic musculoskeletal pain in a sample of 
patients from primary care and to estimate prescription 
costs.
Design Secondary data analyses from a two-arm 
pragmatic randomised controlled trial (COPERS) testing the 
effectiveness of group self-management course and usual 
care against relaxation and usual care for patients with 
chronic musculoskeletal pain (ISRCTN 24426731).
setting 25 general practices and two community 
musculoskeletal services in the UK (London and 
Midlands).
Participants 703 chronic pain participants; 81% white, 
67% female, enrolled in the COPERS trial.
Main outcome measures Anonymised prescribing data 
over 12 months extracted from GP electronic records.
results Of the 703 trial participants with chronic 
musculoskeletal pain, 413 (59%) patients were prescribed 
opioids. Among those prescribed an opioid, the number of 
opioid prescriptions varied from 1 to 52 per year. A total 
of 3319 opioid prescriptions were issued over the study 
period, of which 53% (1768/3319) were for strong opioids 
(tramadol, buprenorphine, morphine, oxycodone, fentanyl 
and tapentadol). The mean number of opioid prescriptions 
per patient prescribed any opioid was 8.0 (SD=7.9). A 
third of patients on opioids were prescribed more than 
one type of opioid; the most frequent combinations were: 
codeine plus tramadol and codeine plus morphine. The 
cost of opioid prescriptions per patient per year varied 
from £3 to £4844. The average annual prescription cost 
was £24 (SD=29) for patients prescribed weak opioids 
and £174 (SD=421) for patients prescribed strong opioids. 
Approximately 40% of patients received >3 prescriptions 
of strong opioids per year, with an annual cost of £236 per 
person.
Conclusions Long-term prescribing of opioids for chronic 
musculoskeletal pain is common in primary care. For 
over a quarter of patients receiving strong opioids, these 
drugs may have been overprescribed according to national 
guidelines.
trial registration number ISRCTN 24426731.
IntrODuCtIOn
‘Few things a doctor does are more important 
than relieving pain … pain is soul destroying.’1 
These words from Marcia Angell, former 
editor in chief of the New England Medical 
Journal, succinctly illustrate the therapeutic 
need for pain relief. However, prescribers 
have to balance both benefits and harm to 
patients from pharmacological treatment. 
Untreated pain can cause both physical and 
mental distress. One in five people suffer 
from chronic pain, the most common sources 
being back pain (24%) or osteoarthritis 
(35%).2 3 Findings from the Global Burden 
of Disease study highlight musculoskeletal 
conditions as the largest cause of disability in 
the UK.4 Pain is the main symptom of many 
musculoskeletal conditions and it is closely 
associated with depression, anxiety, fatigue 
and sleep deprivation. The WHO recognises 
chronic musculoskeletal pain as a global 
priority and aims to better alert nations to the 
health and economic costs brought about by 
musculoskeletal conditions.5 
Opioids are a popular form of analgesia. 
Up to 90% of individuals presenting to pain 
strengths and limitations of this study
 ► This study focuses on the economic aspects of pre-
scribing opioids in primary care.
 ► This study uses individual patient-level data to 
quantify opioid prescribing for people with muscu-
loskeletal pain.
 ► This study looks at the coprescribing of opioids in 
primary care.
 ► This study does not look at longitudinal changes in 
prescribing opioids to patients with chronic muscu-
loskeletal pain.
 ► This study does not attempt to relate opioid pre-
scriptions with treatment effectiveness.
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centres receive opioids.6 There is a lack of evidence 
supporting the efficacy of opioids for chronic non-ma-
lignant pain management. Several studies have demon-
strated that opioids achieve negligible improvements 
in pain, function and quality of life.7–10 In addition, as 
prescribed doses of opioids increase so does the risk of 
adverse effects such as depression, anxiety, headaches, 
insomnia, inadvertent overdose and death.11 According 
to a UK Office of National Statistics report,12 accidental 
drug overdose is rising, with the highest number recorded 
since comparable records began in 1993. Of the 3346 
drug poisoning deaths registered in 2014, 53% involved 
an opiate drug.12 The UK guidelines on chronic pain 
management for people with low back pain and osteo-
arthritis13–16 recommend weak opioids as a second-line 
treatment when the first-line medication (non-steroidal 
anti-inflammatory drugs, paracetamol or cyclo-oxy-
genase-2 inhibitors) is ineffective or not tolerated. Strong 
opioids are to be only prescribed for unremitting cases 
and even then for short-term use only, stepping patients 
down to weaker opioids as appropriate, or removing alto-
gether if not effective.15
In past years, there has been a range of publications from 
both media and the medical profession suggesting that 
prescribed opioid doses are too high and are prescribed 
for too long, actually endangering patients.17–19 An edito-
rial in The BMJ entitled: ‘Opioids in the UK: What is the 
problem?’20 concisely summarised concerns from the 
growing qualitative literature on the overprescription 
of opioids for chronic non-malignant pain. There is a 
growing apprehension that the rise in drug-related deaths 
parallels a rise in opioid prescriptions.9 21–23 However, this 
is an argument based on evidence from the USA, where 
rising numbers of deaths have involved prescription drug 
overdoses.24–26 There are few reliable data on opioid 
prescriptions in the UK to infer whether overprescription 
is an issue.
In this study, our aim was to explore opioid prescribing 
in a sample of patients with chronic musculoskeletal pain 
in primary care and to estimate the associated costs. We 
conducted secondary analyses of prescription data from 
the COPERS trial: a randomised, multicentre, pragmatic 
trial of a non-pharmacological group intervention for 
people with chronic musculoskeletal pain conducted 
across 27 general practices and musculoskeletal services 
across the UK.27–29 We undertook a secondary analysis 
looking at the entire cohort of patients to characterise 
patterns of opioid prescription and to estimate the opioid 
prescription cost. We also looked at the regional differ-
ences in opioid prescribing between two UK geographical 
areas —London and the Midlands.
MethODs
Data sources and study characteristics
We used an anonymised database from the COPERS trial 
that contained the prescription data for the 703 partici-
pants. Study design, setting and participants' characteristics 
are described in detail elsewhere.28 29 Briefly, COPERS 
was a multicentre, pragmatic, randomised controlled 
effectiveness and cost-effectiveness trial conducted in the 
UK from 2011 to 2012. Seven hundred and three adults 
with musculoskeletal pain were randomised using a ratio 
1.33:1 to intervention (n=403) or control (n=300). In 
the intervention group, the participants had usual care 
and were offered a group self-management intervention 
using cognitive behavioural approaches for the non-phar-
macological management of chronic pain (the COPERS 
course). The primary outcome was pain-related disability 
at 12 months (Chronic Pain Grade disability subscale). 
There was a wide range of secondary outcome measures 
which included the Hospital Anxiety and Depression 
Scale, healthcare resource use and EQ-5D-3L. Healthcare 
resource use data included information on the number of 
contacts with primary and secondary healthcare services, 
and prescribing data which were collected from partici-
pants’ GP electronic records at 12 months. The study did 
not find any significant differences in prescribing opioids 
between the intervention and control groups. No serious 
adverse events (related or not related to opioid use) 
were reported in either arm of the trial.29 We therefore 
conducted cohort analyses using data for both groups to 
characterise opioid prescribing for people with chronic 
musculoskeletal pain.
Participants
The characteristics of study participants and recruitment 
procedures are described elsewhere.27 Briefly, partici-
pants were adults (≥18 years) with musculoskeletal pain 
of at least 3 months’ duration. Causes of pain included, 
but were not restricted to: osteoarthritis, back pain, 
chronic widespread pain and fibromyalgia. Participants 
were recruited in the UK (London and the Midlands) 
from primary care, community musculoskeletal pain 
services and secondary care pain services. Exclusion 
criteria were: inability to give informed consent, not 
fluent in English, chronic pain arising from active malig-
nant disease or inflammatory arthritis, terminal illness, or 
serious uncontrolled mental health or substance abuse 
preventing individuals from participating in the group 
sessions. The demography of the study participants was: 
67% female, mean age 60 years (52 years in London and 
67 in Midlands) and 81% white British.
Prescription analysis
We extracted and anonymised prescribing data over 12 
months from participants’ GP electronic records. The 
data set included information on: formulation, dose/
strength and the number of prescription items for each 
participant. A ‘prescription’ refers to a single medicine 
prescribed by a doctor on a prescription form. The 
data set contained 40 649 prescriptions in total; these 
included other items as well as opioids. Opioids were 
identified in the data set by their generic (non-propri-
etary) names using the British National Formulary clas-
sification system.30 Searches were conducted for strong 
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opioids (buprenorphine, diamorphine, dipipanone, 
fentanyl, morphine, oxycodone, papaveretum, pentaz-
ocine, pethidine, tapentadol and tramadol) and weak 
opioids (codeine, dihydrocodeine and meptazinol). 
We also searched for combination formulations which 
contained weak opioids: co-codamol (codeine phos-
phate/paracetamol) and co-dydramol (dihydrocodeine/
paracetamol). The searches were conducted using wild-
cards and the VLOOKUP option in Microsoft Excel. 
The multivariate analysis of variance (MANOVA) was 
conducted using IBM SPSS Statistics V.22. The cost of 
opioid prescriptions was calculated using the Prescription 
Cost Analysis 2012 database31 using a net ingredient cost 
per item (cost without discount and dispensing fees per 
single item prescribed on a prescription form). The list of 
costs used in the study is shown in online supplementary 
appendix 1. We did not compare oral morphine equiv-
alent doses due to lack of consistency in the conversion 
ratios taken from different sources.32–34
results
For the 703 study participants, 413 (59%) were prescribed 
opioids. In total, 3319 opioid prescriptions were issued 
over the 12-month period, of which 53% (1768/3319) were 
for strong opioids (tramadol, buprenorphine, morphine, 
oxycodone, fentanyl and tapentadol). The number 
of opioid prescriptions varied from 1 to 52 per person 
per year. The average number of opioid prescriptions 
per patient was 8.0 (SD=7.9). Table 1 shows the annual 
numbers of opioid prescriptions and their costs. The cost 
per prescription varied from £4 to £63 with oxycodone 
being the most costly opioid prescription. The overall 
cost of all prescribed opioids during the 12-month study 
period was £44 491 (on average £63.29 per participant).
Figure 1 shows the proportions of prescribed opioids. 
Oral opioids comprised 86.9%, transdermal 13.0% and 
parenteral 0.1% of all opioids prescribed. The most 
frequently prescribed opioid was codeine (47%), which 
also included combination formulations co-codamol 
(codeine phosphate/paracetamol) and co-dydramol 
(dihydrocodeine/paracetamol). Tramadol was the most 
frequently prescribed strong opioid (26%), followed 
by buprenorphine (12%), morphine (9%) and oxyco-
done (6%). Parenteral morphine was prescribed to one 
patient only, although we do know whether this was for 
chronic pain or for acute pain management. Figure 2 
illustrates the coprescribing of different types of opioids 
in the cohort of patients with chronic musculoskeletal 
pain. A combination of opioids was prescribed to 32% 
(132/413) of patients. Among these, 112 (27%) people 
received two different types of opioids, 17 (4%) three 
types, and 3 people (1%) were prescribed more than 
three types of opioids. The most frequent combina-
tion of opioids was codeine plus tramadol (83 people), 
followed by codeine plus morphine (19 people), codeine 
plus buprenorphine (19 people) and morphine plus 
tramadol (15 people).
Table 2 summarises numbers of people prescribed 
different types of opioids in the entire cohort and in the 
two samples (London and the Midlands). The propor-
tion of people with musculoskeletal pain prescribed 
opioids was higher in the Midlands sample (63%) 
compared with the London sample (56%). Morphine 
was more frequently prescribed in the Midlands (10%) 
compared with London (3.7%). The average number 
of opioid prescriptions per patient was also higher in 
the Midlands sample 8.58 (SD 8.12) compared with the 
London sample 7.33 (SD 7.56), although this differ-
ence was not statistically significant. The proportions 
of patients receiving different combinations of opioids 
were similar in the London and the Midland samples. 
MANOVA tests conducted using prescription numbers 
for different types of opioids showed no significant differ-
ences between London and Midlands samples (p>0.05, 
not shown).
Table 3 summarises prescription characteristics for 
people receiving weak and strong opioids. More than half 
of these patients (56%, 231/413) were prescribed strong 
opioids. Patients taking strong opioids received on average 
10 prescriptions per year with an annual cost of £174 per 
patient. Among these people, 40% received >3 strong 
opioid prescriptions per year, costing on average £236 per 
person. Patients taking weak opioids received on average 
five prescriptions a year with an annual cost of £24 per 
Table 1 Annual numbers of prescriptions and their costs 
(n=413)
Opioid
Number of 
prescriptions Cost (£)
Average cost per 
prescription (£)
Buprenorphine 391 14 204 36
Codeine/
dihydrocodeine 1551 6899 4
Fentanyl 41 2024 49
Morphine 288 3658 13
Oxycodone 183 11 484 63
Tapentadol 9 356 40
Tramadol 856 5864 7
Total 3319 44 491 30
Figure 1 Proportional distribution of opioid prescriptions in 
the overall cohort of patients.
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Figure 2 Network plot showing coprescribing of opioids for 132 patients. Patients are indicated by blue circles with numbers, 
which are linked to prescribed opioids (yellow circles). The size of the circles is proportional to the number of prescribed 
opioids.
Table 2 Number of study participants prescribed opioids and the average number of prescriptions in different samples
Prescription 
characteristics
London (n=320) Midlands (n=383) Full sample (n=703)
n % n % n %
Prescribed opioids 180 56 233 61 413 59
  Buprenorphine 21 6.6 24 6.3 45 6.4
  Codeine 130 40.6 150 39.2 280 39.8
  Fentanyl 5 1.6 3 0.8 8 1.1
  Morphine 9 2.8 35 9.1 44 6.3
  Oxycodone 6 1.9 9 2.3 15 2.1
  Tapentadol 0 0.0 1 0.3 1 0.1
  Tramadol 71 22.2 96 25.1 167 23.8
Single opioid 126 39.4 163 42.6 289 41.1
Combination of opioids 54 16.9 70 18.3 124 17.6
  2 opioids 48 15.0 57 14.9 105 14.9
  3 opioids 6 3.3 11 4.6 16 2.3
  4 opioids 0 0 2 0.8 2 0.5
  5 opioids 1 0.6 0 0 1 0.2
Average number of 
opioid prescriptions over 
12 months
7.3 (SD=7.6) 8.6 (SD=8.1) 8.0 (SD=7.9)
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person. Within this group, 21% of people received >3 
prescriptions per year costing on average £40 per person.
DIsCussIOn
In this study, we characterised opioid prescribing in a 
sample of people with chronic musculoskeletal pain 
recruited from primary care into a trial of a self-manage-
ment intervention. Opioids were prescribed to 59% of 
study participants and 53% of these prescriptions were 
for strong opioids, indicating their frequent prescription 
for patients with chronic musculoskeletal pain. These 
strong opioids included tramadol (26%), buprenorphine 
(12%), morphine (9%) and oxycodone (6%). Approxi-
mately 40% of patients received >3 strong opioid prescrip-
tions per year, suggesting long-term prescribing of strong 
opioids in primary care. According to the national guide-
lines on chronic pain management for people with low 
back pain and osteoarthritis,15 16 strong opioids are to be 
only prescribed in unremitting cases for short-term use, 
stepping down to weaker opioids, or removing altogether 
if not effective.15
Currently, there is no accepted definition of overpre-
scribing. The use of this term largely depends on context; 
it can refer to unnecessary prescription, lack of clinical 
effectiveness or side effects.35–37 In opioid studies, over-
prescription is closely associated with opioid misuse 
and abuse.9 23 38 39 Dunn et al9 analysed the relationship 
between prescribed opioid doses and the risk of over-
dose in 9940 patients with chronic non-malignant pain. 
People receiving daily oral morphine equivalent doses in 
the range of 50–99 mg have a 3.7-fold increase in over-
dose risk, while patients receiving doses of 100 mg or 
more had an 8.9-fold increase in overdose risk compared 
with patients prescribed <20 mg/day.9 Given that opioids 
differ in their potency, formulation and administration 
routes, converting opioid doses to oral morphine would 
be one way of identifying the overprescription of opioids. 
However, there are differences in the conversion ratios to 
oral morphine used in the national guidelines and formu-
laries.32–34 There is also individual variation in patient 
response to opioids in terms of metabolism, distribution 
and receptor dynamics.40 41 Therefore, opioid conversion 
ratios are purely guidelines that provide starting points 
for switching between different opioids for the majority 
of individuals, subject to further assessment and dose 
titration.
In the context of this study, overprescribing can be 
defined as the long-term prescribing of strong opioids (>3 
prescriptions a year). This is consistent with the National 
Institute for Health and Care Excellence guidelines for 
the most common painful conditions (low back pain and 
osteoarthritis), which recommend strong opioids to be 
prescribed for a short time only.15 16 We found that 40% 
of patients receiving opioids for chronic musculoskel-
etal pain may be overprescribed. The estimated cost of 
overprescription was £236 per person per year (table 3). 
According to recent analyses of opioid prescribing in the 
UK primary care, 1.25–1.38 million people with musculo-
skeletal conditions receive long-term opioids.42 Assuming 
that 40% of these people are overprescribed, the cost of 
opioid overprescription may be over £100 million/year. 
This does not include costs associated with the manage-
ment of side effects and overdose. We were unable to 
calculate these costs since there were no opioid-related 
serious adverse events in either arm of the trial.29 The 
trial was not designed to capture non-serious adverse 
events associated with opioid use.
Although our understanding of chronic pain manage-
ment has advanced, the effective treatment of chronic 
pain remains elusive. In the chronic pain management 
guidelines for Australia, Canada, Germany, USA and UK, 
weak opioids are considered a treatment option.15 16 43–45 
Opioids are used to treat both acute and chronic pain, 
despite pain experts being in agreement over their poor 
effectiveness for the latter.46–48 Some reports suggest that 
prescribing opioids for chronic pain may be associated 
with poorer functional outcomes (eg, disability, pain 
intensity, anxiety and depression) compared with other 
treatment strategies.49 50 Since the late 1990s, under 
growing public pressure and aggressive pharmaceutical 
marketing to eliminate pain, physicians globally have 
been ever more proactive in their efforts to identify 
and treat chronic pain. In the UK, the latest published 
data show that from 2005 to 2015 use of analgesics rose 
by 21 million items, increasing costs by £230.1 million.51 
Among opioids, the increase in the number of prescribed 
items was 10.5% for oxycodone, 9.2% for morphine and 
8.9% for buprenorphine.51 Nevertheless, pain intensity 
Table 3 Characteristics of opioid prescriptions in patients receiving strong and weak opioids (n=413)
Prescription characteristics
People receiving strong opioids
n=231
People receiving weak opioids
n=182
Number of patients prescribed opioids 231 (56%) 182 (44%)
Annual number of prescriptions 2332 987
Annual cost per patient £174 £24
Average number of prescriptions a year (SD) 10 (9) 5 (5)
Number of patients receiving >3 prescriptions a year 166 (40%) 88 (21%)
Average cost per patient receiving >3 prescriptions a 
year
£236 £40
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does not improve in patients with chronic pain on higher 
compared with lower opioid doses, indicating poor effi-
ciency in current opioid prescription practice.7–9 Scien-
tific literature is flooded with information on the dangers 
of opioid misuse, abuse and addiction as a recreational 
drug.52–54 However, fatalities from recreational opioid 
misuse are now overshadowed by medically prescribed 
opioid-related deaths; in the USA, these accounts for 
60% of opioid-related deaths,55 and data from the US 
National Center for Health Statistics show that opioid 
deaths have increased above that of the deaths from 
heroin and cocaine combined.24 Physicians have raised 
the alarm about the rise in opioid prescribing in primary 
care, saying that in many cases doses are too high and 
treatments are too long.17–19 56 Current guidelines for 
the management of conditions associated with chronic 
pain14–16 reiterate importance of maintaining physical 
activity, physiotherapy and education programmes. In 
recent decades, a more holistic approach to chronic pain 
management has been taken. New treatments involve 
self-management, coping strategies such as distraction 
or relaxation techniques, and lower doses of pain relief 
medication.57 58 The purpose of chronic musculoskeletal 
pain management is to enable the individual to live with 
the pain, yet limit its impact on their daily functioning, 
consistent with a biopsychosocial model of health.59 
The cost-effectiveness of these therapies is yet to be 
established. The study of a non-pharmacological inter-
vention for people with chronic musculoskeletal pain, 
which generated data for this manuscript, did not find 
any significant effect on pain severity.28 29 However, the 
intervention was found to be cost-effective due to a reduc-
tion in depression and an improvement in health-related 
quality of life.28 29 Researchers recognise the importance 
of assessing multiple outcomes in pain management 
studies and that research in pain management should go 
beyond comparing the clinical effectiveness of different 
treatments, but address questions of ‘what treatment is 
effective, for which patients, on what outcomes, under 
what circumstances, and at what cost’.60
lIMItAtIOns
This study provides a snapshot of opioid prescribing in 
primary care over a period of 1 year; it did not look at 
longitudinal changes in prescribing opioids to patients 
with chronic musculoskeletal pain.
This study focused on the economic aspects of opioid 
prescribing; it did not attempt to relate opioid prescrip-
tions with treatment effectiveness.
Our analysis assumes that all opioid prescriptions were 
for chronic pain and not for acute pain episodes.
COnClusIOns
Long-term prescribing of opioids for chronic muscu-
loskeletal pain is common in primary care. For over a 
quarter of patients receiving strong opioids, these drugs 
may have been overprescribed according to national 
guidelines. The estimated cost of overprescribing opioids 
in UK primary care may be around £100 million/year.
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